Theragnostics enters licensing deal with AAA for Ga-68 PET

By AuntMinnie.com staff writers

September 22, 2021 -- Theragnostics has signed a global licensing agreement with Advanced Accelerator Applications (AAA) to develop and commercialize gallium-68 (Ga-68) one-step PET radiopharmaceuticals.

Theragnostics will receive an upfront payment and will be eligible for future royalties on sales of resulting products under the agreement terms. AAA, a Novartis company, has exclusive rights to commercialize PET radiopharmaceuticals developed under the licensed patent.

The goal is for the technology platform being developed to enable the production of Ga-68 radiopharmaceuticals in a single multidose vial in one step, which has the potential to diagnose a broad range of cancers, company leaders said.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: